20-Year outcomes following conservative management of clinically localized prostate cancer

JAMA

Volumn 293, Issue 17, 2005, Pages 2095-2101

  Albertsen, Peter C ^a   Hanley, James A ^b   Fine, Judith ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ESTROGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; UNITED STATES; DISEASE COURSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; SURVIVAL;

AGED; DISEASE PROGRESSION; ESTROGENS; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 17844402699     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.17.2095     Document Type: Article

References (17)

1. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713-2719.
2. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975-980.
3. Gleason DF. Histologic grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M, ed. Urologic Pathology. Philadelphia, Pa: Lea & Febiger; 1977:171-198.
4. Draisma G, Boer R, Otto SJ, et al. Lead times and over detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95:868-878.
5. Esposti PL. Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biopsy. Scand J Urol Nephrol. 1971;5:199-209.
6. Albertsen PC, Walters S, Hanley JA. A comparison of cause of death determination among men previously diagnosed with prostate cancer and dying in either 1985 or 1995. J Urol. 2000;163:519-523.
7. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst. 2001;93:1822-1823.
8. Holmberg L, Bill-Axelson A, Helegsen F, et al: Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781-789.
9. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
10. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level of <4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246.
11. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172:1297-1301.
12. Murphy GP, Natarajan N, Pontes JE, et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol. 1982;127:928-934.
13. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
14. Schroder FH, Bangma CH. The European Randomized Study of Screening for Prostate Cancer (ERSPC). Br J Urol. 1997;79:68-71.
15. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial (PIVOT). Oncology. 1997;11:1133-1139.
16. Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21(6 suppl):251S-272S.
17. Donovan J, Hamdy F, Neal D, et al; ProtecT Study Group. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7:1-88.